Daniel Morgensztern

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Ramaswamy Govindan, Nathan Page, Daniel Morgensztern et al. · Journal of Clinical Oncology · 2006 · 1.8K citations · Full text

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2022 · 1.4K citations

Version 3.2022, Advanced Lung Disease, Medicine +15

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2021 · 990 citations · Full text

Non–Small Cell Lung Cancer, Version 4.2024

Gregory J. Riely, Douglas E. Wood, David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network · 2024 · 614 citations

Tumor Biology, Actionable Molecular Biomarkers, Advanced Lung Disease +14

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 537 citations · Full text

Dll3-targeted Antibody-drug Conjugate, Medicine, Immunology +6